Coronavirus Drug and Vaccine Studies Are Recruiting Their First Volunteers

This study, says Kalil, is also designed to be more flexible than most drug trials. “This is not just a remdesivir trial,” he says. “It will test as many [COVID-19] therapies as possible, and remdesivir is just the first. Let’s say a couple of months from now, we realize that remdesivir is a good drug, that it works better than placebo…. Then patients receiving the placebo would be offered the drug and we would move on to test another drug. If remdesivir turns out not to be effective, then we would remove it from the study and bring another drug to test against placebo. It’s a dynamic, fast way to run a randomized trial.” The design is a way to accelerate testing of antiviral drugs against COVID-19, since infections are on-going and there is no treatment yet. Meanwhile, other labs are working on developing vaccines that would provide some protection against the virus in the first place. The vaccine study that is furthest along (and which is also overseen by NIAID) is currently recruiting its first participants at Kaiser Permanente Washington Health Research Institute. Unlike the remdesivir trial, this study will enroll healthy volunteers. Dr. Lisa Jackson, lead investigator on the study, says 45 healthy people will be recruited to test three different doses of the vaccine. Kaiser is currently getting thousands of daily online requests from people interested in participating. Researchers are contacting the volunteers by phone to asses...
Source: TIME: Science - Category: Science Authors: Tags: Uncategorized COVID-19 Infectious Disease Source Type: news

Related Links:

This study aimed to assess the prevalence and variables related to perceived stress associated with the COVID-19 pandemic in a sample of Colombian adults using a designed online cross-sectional survey. Adults answered a version of the Perceived Stress Scale (PSS-10) modified for COVID-19 (PSS-10-C), with Cronbach alpha equal to 0.86. In total, 406 individuals aged between 19 and 88 years (M = 43.9; SD = 12.4) agreed to participate in the survey: 61.8% were females, 90.6% had a university degree, 44.1% were health professionals, and 45.7% considered public health policies for preventing the spread of the disease inconsisten...
Source: Cadernos de Saude Publica - Category: International Medicine & Public Health Authors: Tags: Cad Saude Publica Source Type: research
or NN PMID: 32490915 [PubMed - in process]
Source: Cadernos de Saude Publica - Category: International Medicine & Public Health Authors: Tags: Cad Saude Publica Source Type: research
Abstract COVID-19 has created enormous challenges for health systems worldwide, with the rapidly growing number of deaths and critical patients with pneumonia requiring ventilatory support. Alternative methods to control the spread of the disease such as social isolation, extreme quarantine measures, and contact tracing have been used around the world. However, these measures may not be totally effective to fight COVID-19, in step with the necessary national preparations to meet the new patient care demands. A wide range of digital technologies can be used to enhance these public health strategies, and the pandemi...
Source: Cadernos de Saude Publica - Category: International Medicine & Public Health Authors: Tags: Cad Saude Publica Source Type: research
Gov. Inslee said Thursday the state is "getting close" to having enough supplies to reach 20,000 tests per day.
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news
Publication date: Available online 3 June 2020Source: Carbohydrate PolymersAuthor(s): Zhenguang Liu, Lin Yu, Pengfei Gu, Ruonan Bo, Adelijiang Wusiman, Jiaguo Liu, Yuanlaing Hu, Deyun Wang
Source: Carbohydrate Polymers - Category: Biomedical Science Source Type: research
[Premium Times] The Nigeria Centre for Disease Control (NCDC), on Thursday, announced 350 new cases of COVID-19, bringing the total number of confirmed cases in the country to 11,516.
Source: AllAfrica News: Health and Medicine - Category: African Health Source Type: news
This study showed that a five-day regimen is as effective as 10 days–that’s important, doctors say, since it could mean shorter stays in the hospital, which could alleviate some of the burden on the health care system. “Of course we will have to wait for the final review of all the data, but it would be very nice to have an anti-viral that’s efficacious in this terrible illness,” says Dr. Aruna Subramanian, a clinical professor of medicine at Stanford and an investigator on the study. “At least we know that we can help patients with this, and that’s really the bottom line.” T...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized COVID-19 feature Magazine Source Type: news
Gilead, a California-based biopharmaceutical company, released two encouraging reports about remdesivir, an experimental drug that is being tested as a COVID-19 treatment. In one statement, the company said that a large study of remdesivir “met its primary endpoint”: meaning, in this case, that the researchers have concluded that hospitalized patients taking the drug appear to improve faster than patients given a placebo. The study is run by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health and involves severe patients at multiple centers across th...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized COVID-19 Source Type: news
In early April, about four months after a new, highly infectious coronavirus was first identified in China, an international group of scientists reported encouraging results from a study of an experimental drug for treating the viral disease known as COVID-19. It was a small study, reported in the New England Journal of Medicine, but showed that remdesivir, an unapproved drug that was originally developed to fight Ebola, helped 68% of patients with severe breathing problems due to COVID-19 to improve; 60% of those who relied on a ventilator to breathe and took the drug were able to wean themselves off the machines after 18...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized COVID-19 Source Type: news
This study, says Kalil, is also designed to be more flexible than most drug trials. “This is not just a remdesivir trial,” he says. “It will test as many [COVID-19] therapies as possible, and remdesivir is just the first. Let’s say a couple of months from now, we realize that remdesivir is a good drug, that it works better than placebo…. Then patients receiving the placebo would be offered the drug and we would move on to test another drug. If remdesivir turns out not to be effective, then we would remove it from the study and bring another drug to test against placebo. It’s a dynamic, ...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized COVID-19 Infectious Disease Source Type: news
More News: Allergy | Allergy & Immunology | Coronavirus | COVID-19 | Ebola | Ebola Vaccine | Infectious Diseases | Italy Health | Japan Health | MERS | Pneomococcal Vaccine | Pneumonia | SARS | Science | Study | Vaccines | Veterinary Vaccinations